Diversity has become ingrained as a priority in the oncology space, but industry could get stuck discussing existing barriers without formulating clear plans for taking action. FDA Oncology Center of Excellence (OCE) officials, sponsors and the American Association for Cancer Research (AACR) discuss these hurdles and potential next steps at length in a recent Clinical Cancer Research journal article.
Read More
Art and clinical trials proved a winning combination when Revival Research Institute took its screening operation to the largest art fair in the U.S. and returned with results that far exceeded everyone’s expectations.
Read More
In this blog post from WCG Avoca, a collaborative founded with the joint objective of elevating clinical trial quality and bringing key stakeholders in the clinical trial process into greater alignment, Karen Harvey, senior director of the Avoca Quality Consortium, outlines the new ICH draft guideline’s changes to investigator and sponsor responsibilities as well as the newly added data governance section.
Read More
In this guest column, Ken Getz, Professor and Executive Director, Tufts Center for the Study of Drug Development, presents data-driven insights into why adoption of decentralized trial (DCT) methods is lagging.
Read More
